BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets

German Biotech Sets Sights On Cancer Cell Therapies

The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.

map
BioNTech is expanding its global footprint with the purchase of Kite Pharma's neoantigen TCR R&D program and manufacturing plant • Source: Shutterstock

Flush on the success of its mRNA vaccine for COVID-19, BioNTech SE is already planning for the next stage of its business life with the acquisition of the neoantigen T-cell receptor (TCR) R&D program and manufacturing plant from Gilead Sciences, Inc.’s Kite Pharma division. The deal is part of a broader expansion of its oncology development program – which has already shown early signs of progress in the clinic – and global manufacturing footprint.

Mainz, Germany-based BioNTech announced 19 July that it is acquiring Santa Monica, CA-based Kite’s solid tumor neoantigen TCR platform and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.